Ipsen Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Ipsen Bundle
Unlock Strategic Clarity
Curious where Ipsen’s products land—Stars, Cash Cows, Dogs, or Question Marks? This snapshot teases the shifts; the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and clear moves for allocation and growth. Buy the complete report for a ready-to-use Word analysis plus an Excel summary—cut your research time and get strategic clarity you can act on today.
Stars
Onivyde in expanding pancreatic lines
Onivyde sits in a high-growth oncology segment (global oncology drug market >$200bn in 2023) and Ipsen holds meaningful share in approved markets, with evidence driving earlier-line use and rapid demand increase. Pancreatic cancer remains deadly (5-year survival ~12%), supporting strong uptake as trials show benefit. Sustained promotion, trials, and market-access work are required to cement leadership and convert growth into a durable cash engine.
Cabometyx (ex‑US territories)
Cabometyx (ex-US territories) sits as a Star: renal and thyroid oncology are robust growth pools and Ipsen’s ex‑US rights secure solid share across key markets, supported by broad indication coverage and guideline inclusion that sustain momentum. Promotion‑heavy and partnership‑dependent dynamics mean cash in largely offsets cash out; continued investment is required to defend leadership and capture category growth.
Neuroscience growth in therapeutics (Dysport THX)
Therapeutic spasticity (~30% of stroke survivors) and dystonia (≈16–50/100,000) are expanding, and Dysport THX maintains a strong footprint in neuroscience. 2024 real‑world evidence and high physician familiarity are driving adoption, while the global therapeutic botulinum market is growing at roughly a 6–7% CAGR. Continued education, access work and supply reliability are essential to lock in category leadership—keep the gas on.
Rare liver expansion beachhead
High unmet need and accelerating diagnosis across cholestatic diseases are creating a rare liver expansion beachhead for Ipsen; portfolio and label extensions are driving momentum in select countries, with meaningful share where access is secured, though promotion remains intensive.
- Double down on evidence generation
- Invest in centers of excellence
- Prioritize HEOR to win access
Neuroendocrine tumor franchise adjacencies
Neuroendocrine tumor franchise is a Star: specialty oncology centers expanded volumes ~8% in 2024 and Ipsen remains a go‑to partner with growing tumor control and real‑world evidence supporting uptake; persistent field pull‑through and access maintenance are required to convert demand into sustained revenue, so continued investment is warranted as the NET market expands.
- 2024 center volume growth ~8%
- Real‑world tumor control data driving adoption
- Needs field pull‑through and access upkeep
- Maintain investment to protect high share
Oncology's high-growth niches: evidence, access and promotion convert growth into cashflow
Ipsen Stars sit in high‑growth niches: oncology (> $200bn global 2023), NET centers +8% in 2024, Dysport botulinum market CAGR ~6–7%, Onivyde uptake aided by pancreatic 5‑yr survival ~12%. Continued evidence, access and promotion investment required to convert high growth into sustained cash flow.
| Product | Market growth | 2024 metric |
|---|---|---|
| Onivyde | Oncology | Pancreatic uptake↑ |
| Dysport | 6–7% CAGR | High share |
| NET | Specialty oncology | Centers +8% |
What is included in the product
Detailed Word Document
BCG Matrix of Ipsen: evaluates each drug unit as Star, Cash Cow, Question Mark or Dog with investment and divestment guidance.
Customizable Excel Spreadsheet
One-page Ipsen BCG Matrix that clarifies portfolio choices and kills debate—presentation-ready and exportable.
Cash Cows
Dysport (core, established markets)
Dysport in established markets is a classic cash cow for Ipsen, delivering repeat-dose revenue and an entrenched prescriber base; reported 2024 sales were about €1.0bn, underpinning steady free cash flow. High unit margins and modest promotional spend keep operating margins strong, while supply- and infrastructure-led efficiencies have expanded incremental margin. Focus: maintain commercial productivity and milk consistent returns.
Somatuline (lanreotide) in stable geographies
Somatuline (lanreotide) maintains a large installed base in NET and acromegaly with predictable, recurring demand, delivering roughly €1.1bn in annual sales in 2023. Growth is modest but market share remains high in many European and US pockets, with uptake steady. Robust efficiency and patient-support programs keep churn low and margins healthy. Strategy: harvest cashflows while funding lifecycle management and preparing for upcoming competitive and generic pressure.
Decapeptyl (triptorelin)
Decapeptyl (triptorelin) sits in mature oncology/urology categories with reliable volumes and strong formulary positions, delivering approximately €400m in annual sales in 2024 and sustaining attractive margins above Ipsen average. Low market growth but high share means limited incremental promotion is needed beyond account coverage. Optimize manufacturing and distribution to maximize cash conversion and free cash flow.
Long‑tail specialty SKUs with sticky prescribers
Long‑tail specialty SKUs rely on prescriber habit, outcome familiarity, and entrenched protocols, producing low growth but steady, repeatable orders and healthy gross‑to‑net dynamics for Ipsen.
These brands need minimal active promotion beyond access maintenance; focus on squeezing manufacturing and supply costs while preserving service levels to maximize free cash flow.
- Sticky prescribers
- Stable protocols
- Low growth, dependable orders
- High gross‑to‑net
- Minimal sales push
Geographic clusters with entrenched tender wins
Geographic clusters with entrenched tender wins provide locked‑in contracts and repeat tender cycles that delivered predictable revenues for Ipsen; 2024 group sales were €3.63bn, anchoring cash flow stability. Price discipline and operational excellence support high contribution margins even as growth in these clusters is flat; market share remains secure. Focus is on contract renewals and aggressive cost takeout to protect profitability.
- Locked‑in contracts: repeat tenders ensure predictability
- Price discipline + ops excellence: sustain contribution
- Growth flat, share secure
- Priorities: renewals & cost takeout
Protect margins, renew contracts and optimize manufacturing to maximize free cash flow
Dysport €1.0bn (2024), Somatuline €1.1bn (2024 est.), Decapeptyl €400m (2024) are Ipsen cash cows delivering predictable, high-margin cashflow; focus on commercial productivity, lifecycle funding and cost takeout. Long‑tail specialty SKUs and tendered clusters add stable repeat revenues. Priority: protect margins, renew contracts, optimize manufacturing to maximize free cash flow.
| Product | 2024 sales | Role |
|---|---|---|
| Dysport | €1.0bn | High-margin repeat revenue |
| Somatuline | €1.1bn | Stable installed base |
| Decapeptyl | €400m | Mature, low-growth |
Delivered as Shown
Ipsen BCG Matrix
The file you're previewing is the Ipsen BCG Matrix final report you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready document crafted for strategic clarity. Once bought, the same editable file is yours to download, present, or print immediately. No surprises, no revisions needed.
Dogs
Tazverik (tazemetostat) drag
Tazverik (tazemetostat) sits as a Dog for Ipsen: low market share across fragmented indications with slower-than-expected uptake, keeping it around break-even and tying up promotional budget. Competitive alternatives and narrow EMA/FDA labels constrain momentum and prescribing. Candidate for tight spend, partnering, or exit to reallocate capital.
Legacy primary‑care remnants
Legacy primary‑care remnants are non‑core products in slow, low‑growth markets with limited differentiation, generating modest cash but tying up working capital and management oversight. They hold little strategic relevance to Ipsen’s specialty and oncology focus and constrain R&D and commercial allocation. Prune or divest these assets to free resources for higher‑growth specialty initiatives and accelerate portfolio simplification.
Older formulations near end of life
Older formulations sit in a low-growth (≈0–2% in 2024) and low-share quadrant as clinicians shift to newer options, with market share erosion accelerating annually. Price compression—often 50–80% on commoditization—and rising supply overheads are pressuring margins and EBITDA contribution. Increased promotional spend is unlikely to reverse the trajectory. Rationalize SKUs, minimize inventory, and accelerate wind-down to reduce carrying costs.
Fragmented distributor‑only pockets
Fragmented distributor-only pockets in small countries show weak pull-through and high channel friction, where distribution costs and complexity often exceed returns and margins in 2024 reviews.
These pockets are hard to scale without disproportionate effort; Ipsen's 2024 strategic focus prioritized high-growth markets over low-yield territories.
- Low revenue density
- High channel cost-to-revenue
- Consider consolidation or exit
Post‑patent tails in exposed markets
Post‑patent tails at Ipsen face generic and biosimilar competition that in 2024 drove price and volume erosion of c.30% in exposed EU markets; market share is slipping and recovery is unlikely absent new innovation. Turnaround investment is unlikely to be cash‑accretive given low margins and shrinking demand, so prioritize managed decline and redeploy capital to growth assets.
- Impact: price/volume down c.30% (2024)
- Share: declining, low rebound probability
- Capex: turnaround payback unlikely
- Action: manage decline, redeploy capital
Manage decline: cut spend, rationalize SKUs, exit distributors, focus specialty growth
Tazverik and legacy primary‑care remnants sit as Dogs for Ipsen: low share, slow uptake, break‑even positioning and limited strategic fit. Older formulations and post‑patent tails faced c.30% price/volume erosion in EU 2024, pressuring margins and prompting managed decline. Recommend tight spend, SKU rationalization, distributor exits and redeployment to specialty growth.
| Asset | 2024 signal | Growth 2024 | Action |
|---|---|---|---|
| Tazverik | Low share | ≈0% | Partner/exit |
| Legacy PCPs | Low relevance | 0–2% | Divest |
| Post‑patent tails | Margin pressure | ‑30% EU | Manage decline |
Question Marks
Sohonos (palovarotene) FOP launch
Sohonos (palovarotene) targets FOP, an ultra‑rare disorder with prevalence ~1:2,000,000 (~800–1,000 patients globally), so addressable base is tiny and access pathways are complex. Growth runway is meaningful given unmet need, but initial share will be small. Launch demands heavy investment in diagnosis, specialist centers and real‑world evidence. Go big on execution or consider partnering if uptake/traction lags.
Iqirvo (elafibranor) in PBC
Iqirvo (elafibranor) has a new approval in the PBC niche where prevalence ranges 19–402 per million (2024 estimates), but it launches against entrenched therapy obeticholic acid and off‑label UDCA use. Market access, payer wins and real‑world responder rates will determine uptake. Ipsen faces front‑loaded cash burn with an uncertain sales ramp; invest to prove clear differentiation within 12–18 months or pivot fast.
Bylvay life‑cycle expansion
Bylvay sits in a growing rare‑cholestatic segment (PFIC prevalence ~1:50,000–100,000; estimated addressable PFIC patients ~3,000–5,000 across US/EU/JP in 2024), but competition is fierce and share varies widely by indication and country. High evidence generation and market‑access spend are required—payer dossiers and RWE programmes often run into multiple millions. Push aggressively on label breadth and decisive head‑to‑head value data to secure formulary position.
New Dysport indications/geos
New Dysport indications/geos are high-growth opportunities but entry share typically starts low versus established incumbents, requiring targeted education, KOL advocacy and payer access build‑out to scale uptake.
Early commercial returns can be lumpy; fund focused sprints on segments where clinical differentiation and win rates are highest to de‑risk launch investments.
Oncology pipeline add‑ons
Oncology pipeline add‑ons show compelling science and access to expanding markets but lack established share; trials, regulatory submissions and launch setups are consuming cash today while potential upside lies in converting candidates into the next Star.
Prioritize assets with the fastest path to clinical differentiation, clear reimbursement pathways and biomarkers to accelerate market access and ROI.
- High scientific promise, no market share yet
- Ongoing trials/submissions drain cash
- Upside: become next Star if differentiated
- Prioritise speed to differentiation and reimbursement
Tiny patient pools, massive launch spend — pick fastest paths to meaningful differentiation
Sohonos: FOP ~1:2,000,000 (~800–1,000 pts); high unmet need, heavy launch spend. Iqirvo: PBC prevalence 19–402/million (2024); payer hurdles vs obeticholic acid. Bylvay: PFIC ~1:50,000–100,000 (~3,000–5,000 addr. pts US/EU/JP); intense evidence costs. Oncology candidates: high science, no share; trials consume cash—prioritise fastest paths to differentiation.
| Asset | 2024 addr. pts | Est. launch spend ($M) | Time to diff (mo) |
|---|---|---|---|
| Sohonos | 800–1,000 | 50–100 | 18–36 |
| Iqirvo | ~1,000–20,000 | 75–150 | 12–18 |
| Bylvay | 3,000–5,000 | 50–120 | 12–24 |
| Oncology | NA | 100–300 | 24–48 |